Life-science tools · Bioprocessing · Diagnostics
Danaher Corporation
Danaher is a large US life-science and technology company organized into three segments: Biotechnology, Life Sciences and Diagnostics. It owns more than 15 operating companies including Cytiva (bioprocessing), Beckman Coulter, SCIEX, Leica, Cepheid and Radiometer. FY2025 revenue was about $24.6 billion, with Diagnostics the largest segment at $9.9 billion and Biotechnology at $7.3 billion. Recurring sales such as consumables and services make up roughly 82% of revenue, and China accounts for about 11% of total sales. Bioprocessing demand recovered in 2025, lifting Biotechnology segment revenue 8.0%.
DHR Updated Jul 12, 2026 4 AI consumers· 4 recurring
Per the valuechain.wiki graph, Danaher Corporation is directly linked to 1 companies (0 supply, 1 revenue relationships) and reaches 5 companies within two hops; the links are backed by 5 dated sources, 3 of them primary filings (as of 2026-07-12).
Financials & Segments
- Total revenue · approx. $24.6B (FY2025)
- Segments · Biotechnology · Life Sciences · Diagnostics
Revenue from
- 병원·임상검사실 (진단 소모품) High confidence· Revenue 9,941 USD_M · FY2025 · Diagnostics segment sales
The Diagnostics segment (Cepheid, Beckman Coulter, Radiometer) supplies clinical instruments, consumables and software to hospitals, physicians' offices, reference labs and critical-care settings. FY2025 Diagnostics revenue $9.94B, the largest of the three segments, 89% recurring.Confirms EN Danaher Investor Relations Published Jan 28, 2026: Danaher Reports Fourth Quarter and Full Year 2025 Results - 바이오의약품 제조사 (바이오프로세싱) High confidence· Revenue 7,293 USD_M · FY2025 · Biotechnology segment sales
The Cytiva/Pall bioprocessing business supplies chromatography resins, filters, cell-culture media and single-use hardware/consumables to pharma, biopharma and CDMOs. FY2025 Biotechnology segment revenue $7.29B (+8.0%), 88% recurring. Cytiva is specced into >90% of global mAb production volume.Confirms EN StockStory Published Oct 23, 2025: DHR Q3 2025 Deep Dive: Bioprocessing, Diagnostics, and Productivity Initiatives - 삼성바이오로직스 (싸이티바 바이오프로세싱) High confidence· Market share 90% · Cytiva coverage of global mAb production volume
CDMOs/biomanufacturers such as Samsung Biologics use Cytiva chromatography resins (MabSelect Protein A), purification filters and cell-culture media in commercial production. Cytiva leads the Korean resin/media market. Contract values not disclosed.Confirms KO The Korea Economic Daily Published Apr 10, 2025: Cytiva, a bioprocessing materials leader, launches two Protein A resins for antibody therapeutics
Pays to
- 전자·계측 부품 공급사 (장비 제조) Medium confidence
Danaher's manufacturing uses metallic-based components, electronic components and OEM products among other raw materials, sourced from a large number of suppliers worldwide with no single supplier material to the Company (10-K). Amounts not disclosed. - 화학·수지·플라스틱 원재료 공급사 (소모품·석유화학 기반) Medium confidence
Chemistries, plastics and other petroleum-based products feed consumables (resins, filters, reagents, media) and instrument manufacturing. Oil and gas prices indirectly affect freight, utilities and purchased-material costs (10-K). Amounts not disclosed.
Value-chain ripple (2 tiers)
Following node-to-node links up to 2 tiers; each firm is shown once, at its nearest tier.
| Company | Chain | '21 | '22 | '23 | '24 | '25 | YTD |
|---|---|---|---|---|---|---|---|
| Bristol-Myers Squibb Company | lead2 | +2.9 | +19 | -26.1 | +15.8 | +0.1 | +28.1 |
| Gilead Sciences, Inc. | lead2 | +30 | +23.6 | -2 | +18.7 | +36.6 | +24.5 |
| Pfizer Inc. | lead2 | +66.7 | -10.4 | -41.3 | -2.2 | +0.6 | +20.2 |
| LigaChem Biosciences | lead2 | -26.2 | -18.1 | +37.1 | +151 | +60.5 | -54.7 |
| Samsung Biologics | lead1 | -6.8 | +8.6 | +5.8 | +28.7 | +5 | -17.1 |
| Danaher Corporation | node | +48.6 | -19 | -1.2 | -0.3 | +0.4 | -8.9 |
YTD as of 2026-09-04 · source: Yahoo Finance
Danaher Corporation operates across Life-Science Tools, S&P 500. It is -8.9% in 2026. The stock (-8.9%) and its demand side (avg -17.1%) are moving in step. Bioprocessing demand recovered in 2025, lifting Biotechnology segment revenue 8.0%.
Analysis generated from returns as of 2026-09-04